Compugen (NASDAQ:CGEN) Posts Earnings Results, Beats Estimates By $0.01 EPS

Compugen (NASDAQ:CGEN) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01, FiscalAI reports. Compugen had a net margin of 47.56% and a return on equity of 43.64%. The business had revenue of $2.60 million during the quarter, compared to analysts’ expectations of $1.28 million. During the same period last year, the company posted ($0.08) earnings per share.

Here are the key takeaways from Compugen’s conference call:

• MAIA-ovarian remains on track for an interim analysis by Q1 2027, with Compugen estimating placebo-arm median PFS at approximately four months and defining six months or more of PFS for COM701 as clinically meaningful.
• AstraZeneca expanded its rilvegostomig program to 12 Phase III trials with a new study in high-risk muscle-invasive urothelial cancer, supporting Compugen’s potential future milestones of $195 million and mid-single-digit tiered royalties.
• Rilvegostomig data presented at ASCO included 16.8 months of overall survival in first-line biliary tract cancer, which management characterized as encouraging versus historical survival of less than 13 months, although randomized Phase III data are still needed.
• Gilead’s GS-0321 anti-IL-18 binding protein program continues through Phase I dose escalation in monotherapy and combination settings, but Compugen said it remains too early to provide detailed clinical data or timing for disclosure.
• Compugen ended the quarter with approximately $125.3 million in cash and a projected operating runway into 2029; second-quarter revenue increased to $2.6 million while net loss narrowed to roughly $7.0 million.

Compugen Price Performance

Shares of CGEN opened at $2.38 on Wednesday. The firm has a market cap of $225.03 million, a price-to-earnings ratio of 6.43 and a beta of 2.77. The company’s fifty day moving average is $2.25 and its 200-day moving average is $2.27. Compugen has a 12 month low of $1.29 and a 12 month high of $3.23.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on CGEN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compugen in a research report on Friday, July 17th. Leerink Partners dropped their price target on shares of Compugen from $13.00 to $5.00 and set an “outperform” rating on the stock in a research note on Thursday, May 21st. Wall Street Zen lowered Compugen from a “buy” rating to a “hold” rating in a report on Saturday, May 23rd. HC Wainwright reissued a “buy” rating on shares of Compugen in a research report on Tuesday. Finally, Lake Street Capital assumed coverage on Compugen in a research note on Tuesday, April 7th. They issued a “buy” rating and a $6.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

Institutional Investors Weigh In On Compugen

Large investors have recently bought and sold shares of the business. Security National Bank of Sioux City Iowa IA bought a new position in Compugen during the fourth quarter valued at about $38,000. Franklin Resources Inc. bought a new stake in shares of Compugen during the 2nd quarter worth about $56,000. Osaic Holdings Inc. increased its holdings in shares of Compugen by 346.0% during the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 34,045 shares during the last quarter. WINTON GROUP Ltd acquired a new position in shares of Compugen during the 4th quarter valued at about $84,000. Finally, XTX Topco Ltd bought a new position in shares of Compugen in the 4th quarter valued at approximately $104,000. 12.22% of the stock is currently owned by institutional investors.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.